Treatment of essential thrombocythemia during pregnancy with interferon-alpha

Obstet Gynecol. 1996 May;87(5 Pt 2):814-7.

Abstract

Background: Only a few cases of essential thrombocythemia in pregnant women have been reported, and the management of this myeloproliferative disorder during pregnancy remains uncertain. We report a successful pregnancy in a patient who had essential thrombocythemia and who was treated with interferon-alpha, and we review the literature for the outcome of similar patients.

Case: A 32-year-old woman, gravida 4, para 3, aborta 0, presented at 18 weeks' gestation with two episodes of amaurosis fugax and an elevated platelet count of 2300 x 10(9)/L. The initiation of interferon-alpha led to a progressive fall of the platelet level, with no occurrence of thrombotic or hemorrhagic manifestations. Serial ultrasound examinations revealed normal fetal and placental development. The patient was delivered of a male infant at 37 weeks. Both child and placenta were normal on examination.

Conclusion: Our case and the current available data suggest that interferon-alpha may be the best therapeutic option for pregnant patients with essential thrombocythemia in whom myelosuppression is required.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aspirin / therapeutic use
  • Female
  • Humans
  • Infant, Newborn
  • Interferon-alpha / therapeutic use*
  • Male
  • Platelet Aggregation Inhibitors / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Hematologic / diagnosis
  • Pregnancy Complications, Hematologic / therapy*
  • Pregnancy Outcome
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / therapy*

Substances

  • Interferon-alpha
  • Platelet Aggregation Inhibitors
  • Aspirin